AOA Dx, Inc (“AOA”) is developing a groundbreaking biomarker technology platform centered on tumor glycolipids. The primary objective is to detect early-stage Ovarian cancer by quantifying circulating gangliosides, addressing a critical unmet need in women’s health. AOA’s revolutionary AKRIVIS GDTM is a non-invasive “liquid biopsy” blood test that has the potential to save up to 100,000 women’s lives annually, a large population that also represents a sizable market opportunity. With a pivotal multicenter clinical validation study and stellar team, AOA is poised to usher in a brighter future for women’s health diagnostics.
Recent News
MILESTONESSeries Seed-1 Series Seed-1 Follow On |
TARGET CANCERSOvarian Cancer |
FOCUS SECTORDiagnostics & Management |
WHY WE INVESTED
SERIES SEED-1 (2023)
Ovarian cancer is among the most deadly cancer types. Diagnosis is commonly made at later stages where treatment options are limited, leading to a 5-year survival rate of only 28%. AOA’s innovative test offers the promise of earlier detection of Ovarian cancer when symptoms first present, and early detection saves lives. As an impact investment, CANCER FUND sees AOA Dx as a potential breakthrough in improving early cancer detection and opening up more effective treatment options for patients.
SERIES SEED-1 FOLLOW ON (2024)
We continue to believe in the potential benefits of early detection of Ovarian cancer and the progress made by AOA since our Series Seed-1 investment. This follow on investment reinforces our support for AOA and retains our equity investment position.